Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil

  • Liang, Yong (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Bu, Jun-Guo (Zhujiang Hospital of Southern Medical University) ;
  • Cheng, Jin-ling (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Gao, Wei-Wei (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Xu, Yao-Can (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Feng, Jian (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Chen, Bo-Yu (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Liang, Wei-Chao (Department of Oncology, The People's Hospital of Guiping City of Guangxi) ;
  • Chen, Ke-Quan (Department of Oncology, The People's Hospital of Guiping City of Guangxi)
  • Published : 2015.09.02


Purpose: To investigate the efficacy and safety of selective radiotherapy after distant metastasis of nasopharyngeal carcinoma (NPC) treated with dose-dense cisplatin plus fluorouracil. Materials and Methods: Eligible patients were randomly assigned to a study group treated with dose-dense cisplatin plus fluorouracil following selective radiotherapy and a control group receiving traditional cisplatin plus fluorouracil following selective radiotherapy according to a 1:1 distribution using a digital random table method. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate, relapse or progression rate in the radiation field and treatment toxicity. Results: Of 52 patients in the study group, 20 cases underwent radiotherapy., while in the control group of 51 patients, 16 underwent radiotherapy. The median PFS, median OS, survival rates in 1, 2 and 3 years in study and control group were 20.9 vs 12.7months, 28.3 vs 18.8months, 85.2%vs 65.9%, 62.2% vs 18.3%, and 36.6%vs 5.2% (p values of 0.00, 0.00, 0.04, 0.00 and 0.00, respectively). Subgroup analysis showed that the median OS and survival rates of 1, 2, 3 years for patients undergoing radiotherapy in the study group better than that in control group( 43.2vs24.1 months, 94.1% vs 86.7%, 82.4% vs 43.3%, 64.7% vs 17.3%, (p=0.00, 0.57, 0.04 and 0.01, respectively). The complete response rate, objective response rate after chemotherapy and three months after radiotherapy, relapse or progression rate in radiation field in study group and in control group were 19.2% vs 3.9%, 86.5% vs 56.9%, 85% vs 50%, 95% vs 81.3% and 41.3% vs 66.7% (p =0.03, 0.00, 0.03,0.30, 0.01 respectively). The grade 3-4 acute adverse reactions in the study group were significantly higher than in the control group (53.8% vs 9.8%, p=0.00). Conclusions: The survival of patients benefits from selective radiotherapy after distant metastasis of NPC treated with dose-dense cisplatin plus fluorouracil.


  1. Aapro MS, Bohlius J, Cameron DA, et al (2011). 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer, 47, 8-32.
  2. Agnese D, Belgioia L, Bacigalupo A, et al (2014). Prolonged complete remission after induction chemotherapy followed by chemoradiation with tomotherapyin metastatic nasopharyngeal cancer. Anticancer Res, 34, 5075-8.
  3. Abbasi AN, Hafiz A, Ali N, et al (2013). Plan dose evaluation of 3D-CRT of nasopharyngeal cancer in Pakistan. Asian Pac J Cancer Prev, 14, 5989-93.
  4. Aoki H, Ogura R, Tsukamoto Y, et al (2013). Advantages of dosedense methotrexate protocol for primary central nervous system lymphoma: comparison of two different protocols at a single institution. Neurol Med Chir, 53, 797-804.
  5. Bensouda Y, Kaikani W, Ahbeddou N, et al (2011). Treatment for metastatic NPC. european annals of otorhinolaryngology, Head and Neck Diseases, 128, 79-85.
  6. Chen MY, Jiang R, Guo L, et al (2013). Locoregional radiotherapy in patients with distant metastases of NPC at diagnosis. Chin J Cancer, 32, 604-13.
  7. Crawford J, Caserta C, Roila F, et al (2010). Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol, 21, 248-51.
  8. Du C, Ying H, Zhou J, et al (2013). Experience with combination of docetaxel, Cisplatin plu-s 5-fluorouracil chemotherapy, and intensity-modulatedradiotherapy for locoregionally advanced NPC. Int J Clin Oncol, 18, 464-71.
  9. Guenne C, Fayette J, Cosmidis A, et al (2014). Curative treatment can be an option for patients with metastatic squamous cell cancer of the head and neck. Drug Des Devel Ther, 8, 2549-53.
  10. Fandi A, Bachouchi M, Azli N, et al (2000). Long-term diseasefree survivors in meta-static undifferentiated carcinoma of nasopharyngeal type. J ClinOncol, 18, 1324-30.
  11. Havlin KA1, Kuhn JG, Myers JW, et al (1989). High-dose cisplatin for locally advanced or met-astatic head and neck cancer. A phase II pilot study. Cancer, 63, 423-7.<423::AID-CNCR2820630304>3.0.CO;2-C
  12. Hingorani M, Dixit S, Johnson M, et al (2015). Palliative radiotherapy in the presence of well-controlled metastatic disease after Initial chemotherapy may prolong survival in patients with metastatic esophageal and gastric cancer. Cancer Res Treat.
  13. Hudis C, Dang C (2015). The development of dose-dense adjuvant chemotherapy. Breast J, 21, 42-51.
  14. Jamshed A, Hussain R, Iqbal H. (2014). Gemcitabine and cisplatin followed by chemo-radiati-on in advanced NPC. Asian Pac J Cancer Prev, 15, 899-904.
  15. Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
  16. Kang M, Liu WQ, Qin YT, et al (2013). Long-term efficacy of microwave hyperthermia combined with chemoradiotherapy in treatment of NPC with cervical lymph node metastases. Asian Pac J Cancer Prev, 14, 7395-400
  17. Kertmen N, Aksoy S, Cengiz M, et al (2015). Comparison of three different induction regimens for nasopharyngeal cancer. Asian Pac J Cancer Prev, 16, 59-63.
  18. Kong FF, Ying H, Du CR, et al (2014). Effectiveness and toxicities of intensity-modulated radiation therapy for patients with T4 nasopharyngealcarcinoma. PLoS One, 9, 91362.
  19. Kua VF, Ismail F, Chee Ee Phua V, et al (2013). Carboplatin/5-fluorouracil as an alternat-ive to cisplatin/5- fluorouracil for metastatic and recurrent head and necksquamous cellcarcinoma and NPC. Asian Pac J Cancer Prev, 14, 1121-6.
  20. Kumar A, Hoskins PJ, Tinker AV (2015). Dose-dense paclitaxel in advanced ovarian cancer. Clin Oncol (R Coll Radiol), 27, 40-7.
  21. Lee AW, Ng WT, Chan YH, et al (2012) . The battle against nasopharyngeal cancer. Radiother Oncol, 104, 272-8.
  22. Li MY, Liu JQ, Chen DP, et al (2014). Glycididazole sodium combined with radiochemothe- rapy for locally advanced NPC. Asian Pac J Cancer Prev, 15, 2641-6.
  23. Lutz ST, Jones J, Chow E (2014). Role of radiation therapy in palliative care of the patient with cancer. J Clin Oncol, 32, 2913-9.
  24. Nagamata M, Okuma Y, Yamada Y, et al (2014). Crucial role of treatment with palliative intent for a patient with advanced thymic carcinoma. OncolLett, 8, 513-6.
  25. Ng WT, Lee MC, Hung WM, et al (2011). Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for NPC. Int J Radiat Oncol Biol Phys, 79, 420-8.
  26. Pandey KC, Revannasiddaiah S, Pant NK, et al (2013). Palliative radiotherapy in locally advanced head and neck cancer after failure of induction chemotherapy:comparison of two fractionation schemes. Indian J Palliat Care, 19, 139-45.
  27. Peto R, Davies C, Godwin J, et al (2012). Comparisons between different poly Chemotherapy regimens forearly breast cancer: meta-analyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet, 379, 432-44.
  28. Veronesi A, Zagonel V, Tirelli U, et al (1985). High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol, 3, 1105-8.
  29. Wang TL, Tan YO (1991). Cisplatin and 5-fluorouracil continuous Infusion for metastaticNPC. Ann Acad Med Singapore, 20, 601-3.
  30. Xiao WW, Huang SM, Han F, et al (2011). Local control, survival, and late toxicities of locally advanced NPC treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: longterm results of a phase 2 study. Cancer, 117, 1874-83.
  31. Xu T, Hu C, Zhu G, et al (2012). Preliminary results of a phase III randomized studycomparing chemotherapy neoadjuvantly or concurrently withradiotherapy for locoregi-onally advanced NPC. Med Oncol, 29, 272-8.
  32. Yin H, Lu K, Qiao WB, et al (2014). Whole-liver radiotherapy concurrent with chemotherapy as a palliative treatment for colorectal patients withmassive and multiple liver metastases: a retrospective study. Asian Pac J Cancer Prev, 15, 1597-602.
  33. Zeng L, Tian YM, Huang Y, et al (2014). Retrospective analysis of 234 NPC patients with distant metastasis at initial diagnosis:therapeutic approaches and prognostic factors. PLoS One, 9, 108070.